Millions of Americans who purchase drugs from Canada could lose access due to a CBP rule set to take effect later this month. This change intends to collect tariffs and prevent illegal drugs from entering the U.S.
The rule suspends the de minimis exemption, which previously allowed shipments under $800 to pass customs more easily, requiring additional data and a bond guarantee for medications mailed from outside the U.S. Roughly 2.3 million Americans currently buy their drugs abroad.
The Trump administration has prioritized lowering drug prices through most-favored-nation deals and the TrumpRx website, resulting in a 3.1% year-over-year drop in U.S. prescription drug prices. However, advocates argue this doesn’t cover all drugs for all people and conditions.
A study by the Campaign for Personal Prescription Importation indicated that a 3-month supply of apixaban (apixaban) could cost $565 from a Canadian pharmacy, compared to $1,017 from Amazon or $1,029 from GoodRx.
Concerns have been raised by lawmakers, particularly in Florida, regarding access to affordable medications for constituents who rely on imported drugs. Existing tariffs on Canada have already increased medication costs for some individuals. Susan Hooper, a Toledo, Ohio resident, relies on medications purchased from a Canadian pharmacy and notes increases in her medication costs due to tariffs. CBP The administration continues to work to ensure Americans have access to low-cost pharmaceuticals, but questions remain about the impact of the new rule on patients seeking affordable medicine.